ChileTuberculosis profile
Population  2015 18 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.47 (0.46–0.47) 2.6 (2.6–2.6)
Mortality (HIV+TB only) 0.02 (<0.01–0.097) 0.11 (0–0.54)
Incidence  (includes HIV+TB) 3 (2.5–3.4) 16 (14–19)
Incidence (HIV+TB only) 0.15 (0.11–0.19) 0.82 (0.63–1)
Incidence (MDR/RR-TB)** 0.061 (0.04–0.082) 0.34 (0.22–0.46)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.13 (0.077–0.17) 0.98 (0.67–1.3) 1.1 (0.74–1.5)
Males 0.12 (0.083–0.16) 1.7 (1.4–2.1) 1.9 (1.4–2.3)
Total 0.25 (0.19–0.3) 2.7 (2.5–3) 3 (2.5–3.4)
TB case notifications, 2015  
Total cases notified 2 657
Total new and relapse 2 569
          - % tested with rapid diagnostics at time of diagnosis 1%
          - % with known HIV status 63%
          - % pulmonary 80%
          - % bacteriologically confirmed among pulmonary 86%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 87% (75–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.17 (0.14–0.2)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 213 13%
          - on antiretroviral therapy    
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  42
(26–57)
Estimated % of TB cases with MDR/RR-TB 1.5% (0.88–2.3) 5.6% (2.6–10)  
% notified tested for rifampicin resistance 58% 62% 1 554
MDR/RR-TB cases tested for resistance to second-line drugs   30
Laboratory-confirmed cases MDR/RR-TB: 30, XDR-TB: 2
Patients started on treatment **** MDR/RR-TB: 26, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 58% 2 353
Previously treated cases, excluding relapse, registered in 2014 14% 57
HIV-positive TB cases, all types, registered in 2014 40% 225
MDR/RR-TB cases started on second-line treatment in 2013 21% 14
XDR-TB cases started on second-line treatment in 2013   0
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2016  
National TB budget (US$ millions) 2.3
Funding source: 11% domestic, 0% international, 89% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-01-24 Data: www.who.int/tb/data